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EDITORIAL REVIEW
Monoclonal immunoglobulin deposition disease (Randall type).
Relationship with structural abnormalities of immunoglobulin
chains
The presence of a monoclonal proliferation of plasma cells or
lymphocytes, irrespective of its overt malignant or apparently
benign character, may result in a number of severe complications,
most of which relate to monoclonal immunoglobulin (Ig) secre-
tion. Several diseases featuring tissue deposition of monoclonal
Ig, Ig chains or fragments tentatively may be classified according
to the organization of the deposits by electronmicroscopy (Table
1). The kidney is consistently involved in these deposition dis-
eases, often as the predominant visceral involvement. The most
frequent diseases are Ig light chain (L)-related (AL) amyloidosis
and L chain deposition disease (LCDD). Although the deposits in
AL-amyloidosis contain monoclonal L chains or L chain frag-
ments, the denomination of LCDD is only used for the disease
featuring non-amyloid electron-dense granular deposits described
by Randall et al [121. Soon after this first description, monoclonal
heavy (H) chains were found together with L chains in the tissue
deposits from certain patients [13], and the terms of monoclonal
Ig deposition disease (MIDD) [13, 14] and of L and H chain
deposition disease (LHCDD) [15, 16] were proposed. More
recently, deposits containing monoclonal H chains in the absence
of detectable L chains were observed in patients affected with
otherwise typical Randall's disease (H chain deposition disease,
HCDD) [9]. Gallo et al [15] and Buxbaum et al [16] used the
denomination of MIDD for LCDD, LHCDD and amyloidosis.
Since the term LCDD does not stand for amyloidosis, we feel that
it is preferable to restrict the name MIDD to LCDD and disorders
characterized by the same pathological appearance, that is,
LHCDD and HCDD (although any disease listed in Table 1 might
be called MIDD). Indeed, the distinction between amyloidosis
and Randall's disease is likely justified since the probable mech-
anism of amyloidogenesis which implicates one-dimensional elon-
gation of a pseudocrystalline structure (fibrils) [17] is generally
different from that of the amorphous precipitation of L chains in
LCDD. It seems useful to precise "Randall type" when referring
to MIDD excluding amyloidosis and the other deposition dis-
eases. However, for the sake of brevity, this precision will be
omitted below.
During the last two decades, a large number of structural data
have accumulated in AL-amyloidosis (thoroughly reviewed in
[18]). In contrast, until very recently virtually no data were
available in MIDD. Recent studies, most performed using molec-
ular biology methods, provided sequence data on L and H chains
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in MIDD, which prompted us to briefly review these results. Since
the clinical and pathological features of MIDD were the subject of
several review papers [14—16, 19—21], we will merely recall them
briefly.
Clinical and pathological features of MIDD
In clinical and pathological terms, LCDD, LHCDD and HCDD
are essentially similar and may be envisaged together. Renal
symptomatology often dominates the clinical presentation since
the vast majority of the patients exhibit glomerular symptoms.
Abundant albuminuria often leads to a full-blown nephrotic
syndrome associated with microscopic hematuria. Hypertension is
rarely prominent. The renal function deteriorates rapidly and in
some instances the associated glomerular symptoms in rapidly
progressive renal failure mimics some forms of crescentic glomer-
ulonephritis. This further emphasizes the value of an early renal
biopsy. Interestingly, these patients do not present with the
"naked" renal insufficiency with oliguria common in the usual
forms of myeloma. In patients with heart, liver or other organ
involvement the diagnosis can be readily suspected. It is easier in
patients with multiple myeloma, although there are no clinical
clues that allow the differentiation of MIDD from amyloidosis.
The morphological features of these disorders are well estab-
lished, and in retrospect many cases of undiagnosed "para-
amyloid" or unidentified glomerulonephritis or even "diabetic"
glomerulosclerosis in patients with normal glycemic control were
presumably MIDD. Paradoxically, MIDD is a glomerular disease,
but the lesion that makes it easy to recognize by the renal
pathologist is a tubular lesion because in early cases there are
often conspicuous tubular abnormalities, whereas the glomerular
damage may remain minimal for prolonged periods.
The tubular lesions by light microscopy are characterized by the
deposition of a refractile, eosinophilic, PAS-positive, ribbon-like
material along the outer part of the tubular basement membrane
which is found in virtually all patients with MIDD. The deposits
predominate around the distal tubules, Henle's loops, and in some
instances around the collecting tubules. The tubular epithelium is
often flattened and atrophied. Bence-Jones casts are absent or
rare. By immunofluorescence (IF), smooth linear peritubular
deposits of monotypic Ig chains constitute the hallmark of the
disease (Fig. 1). The deposits predominate around the loops of
Henle and the distal tubules, but they are often present around
the proximal tubules as well. Bright staining may be present even
in cases where only occasional PAS-positive deposits surround the
tubules by light microscopy. By electron microscopy, finely or
coarsely granular electron-dense deposits delineate the outer
aspect of the tubular basement membranes. They appear to be in
contact with a well preserved basal lamina. The deposits are
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Table 1. Diseases featuring tissue deposition of monoclonal Ig-related material
Deposits
Organized Non-organized (granular)
MIDD "Non-Randall"Fibrillar Microtubular Crystals
amyloidosis [1]
AL
AH
nonamyloida
cryoglobulinemia
kidney [2]
GOMMID
Fanconi's syndrome [3, 4]
others [4, 5]
("Randall type")
LCDD
LHCDD
HCDD
most IgA or 1gM L6]
Abbreviations are: AL, light chain amyloidosis; Al-I, heavy chain amyloidosis [7]; GOMMID, glomerulonephritis with organized microtubular
monoclonal immunoglobulin deposits [81; MIDD, LCDD, LHCDD, HCDD, monoclonal immunoglobulin, light, light and heavy, heavy chain [9]
deposition disease.
"Non-amyloid fibrillar and microtubular monoclonal or polyclonal Ig deposits were reported under the denomination of immunotactoid
glomerulopathy [10, 11]. Microtubular deposits appear to be monoclonal more often than flbrillar deposits, and this might represent an entity [8, 11].
Fig. 1. HCDD. IF microscopy with anti-y chain conjugate (kidney biop-
sy). Heavy fixation along tubular basement membranes and smooth
muscle cells in arteriolar walls (original magnification X500).
usually quite large and may protrude into the adjacent part of the
interstitium.
Nodular glomerulosclerosis is the most characteristic glomeru-
lar lesion of MIDD (Fig. 2) [22, 23]. It is present in 60% of MIDD
patients and resembles the glomerular lesions of diabetes mellitus
and some cases of membranoproliferative glomerulonephritis.
The distribution of the nodules is fairly regular with each glomer-
ulus containing several nodules. The glomerular basement mem-
branes are moderately thickened. In addition to abnormalities in
the glomerular tuft, the Bowman's capsule may contain a material
identical to that present in the center of the nodules. In diabetes,
the nodules are markedly argyrophilic and much more irregular in
size within a given tuft, the glomerular capillary loops are
markedly thickened and large aneurysmal dilatations are common
(other lesions such as capsular droplets, exudative "fibrin-caps",
and extensive hyalinosis of the efferent arteriole are not observed
in MIDD). MIDD may also mimic type II membranoproliferative
glomerulonephritis or dense deposit disease. In this disease, the
thickening of the peripheral basement membrane is conspicuous,
with a bright refractile, ribbon-like appearance, but mesangial and
endocapillary cell proliferation is more prominent than that seen
in LCDD. The proliferation usually affects the center and the
periphery of the nodules in an even manner. In contrast, the
Fig. 2. HCDD (same biopsy as in Fig. 1). Nodular glomerulosclerosis,
toluidine blue staining, original magnification x400.
nodules in MIDD contain few or no nuclei and those which are
present are localized at the periphery of the nodules.
In patients with other glomerular lesions, an increase in the
amount of mesangial matrix or in the number of mesangial cells
may be the only abnormality observed. In other patients, the
glomerular basement membranes appear moderately thickened,
bright, and rigid. Others have no evident glomerular lesions by
light microscopy. It has been suggested that the modest increase
in mesangial matrix and cellularity present in some patients
represents an early stage of glomerular disease which will evolve
into nodular glomerulosclerosis with time.
The IF pattern of glomeruli displays considerable heterogene-
ity. In patients with nodular glomerulosclerosis, deposits of mo-
notypic Ig chains are usually found along the peripheral glomer-
ular basement membranes and to a lesser extent in the nodules
themselves. The staining in glomeruli is typically weaker than that
observed along the tubular basement membranes. This may not be
a function of the actual amount of deposited material, since
several cases have been reported in which glomerular IF was
negative despite the presence of large amounts of granular
glomerular deposits by electron microscopy. This led to the
hypothesis that local modification of L chains deposited in the
glomerulus makes their antigenic determinants poorly accessible
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Table 2. Ig chain determinants by immunofluorescence in monoclonal
immunoglobulin deposition disease (Randall type)
Number of
cases
Tissue
deposits
Bone marrow
plasma cells
15 K K
3 K K 20K
2 aK aK
3 A A
1 A yA 5A
1 yA 7A
3 yl yA
1 y4 NDa
a No detectable monoclonal population
Fig. 3. HCDD (same renal biopsy as in Figs. I and 2). Electron microscopy
(original magnification x3,300). Electron dense granular deposits dif-
fusely infiltrating the glomerular capillary basement membrane and
present in mesangial nodules.
[14]. In patients without nodular lesions, the glomeruli are often
negative by IF. Linear Ig chain staining may be present along
Bowman's capsule basement membrane in patients with thicken-
ing of this structure by light microscopy.
Ultrastructural glomerular lesions in LCDD are characterized
by the deposition of a non-fibrillar electron-dense material in the
mesangial nodules and along the glomerular basement membrane
(Fig. 3). This material is usually finely granular, although some
reports mention the presence of coarse granules [22].The depos-
its along the glomerular basement membrane appear as a prom-
inent but thin, homogeneous band delineating the endothelial or
epithelial aspect of the basement membrane. The limits between
the deposits and the basement membrane may be difficult to
distinguish. In rare cases the deposits invade thelamina densa.
Glomerular endothelial cells are separated from this material by
areas of electron-lucent fluffy material. Most authors have not
observed a substructure within the deposits although a few have
described the presence of fibrils within the mesangial nodules
which differ in size and periodicity from those of amyloid. Banded
collagen fibrils have been reported in a few patients [24]. Podo-
cytes usually show extensive spreading. Mesangial proliferation
predominates at the periphery of the nodules. Mesangial interpo-
sition with basement membrane duplication identical to that seen
in membranoproliferative glomerulonephritis has been reported
in patients with nodular glomerulosclerosis. Bowman's capsules
may contain localized dense osmiophilic deposith.
In addition to tubular and glomerular lesions, interstitial fibro-
sis is present in all patients [25]. Interstitial deposits of material
identical to that present in the glomeruli has also been described
in several patients. Arteries, arterioles and peritubular capillaries
all may contain light chain deposits in close contact with their
basement membranes.
The most common underlying disease in MIDD is myeloma.
MIDD was found at post-mortem examination in 5% of myeloma
cases [26]. It often is a presenting symptom leading to the
discovery of myeloma at an early stage. In some patients who first
presented with common myeloma and with normal-sized mono-
clonal Ig without kidney disease, LCDD occurred when the
disease relapsed after chemotherapy, together with Ig structural
abnormalities [13, 14]. Since Melfalan is known to be able to
induce abnormal Ig synthesis probably through Ig gene mutations
[27], this led to suggest that the disease in these patients resulted
from the emergence of a variant clone induced by the alkylating
agent. Apart from myeloma, MIDD may rarely complicate Wal-
denstrom's macroglobulinemia, including its apparently nonsecre-
tory form [28] or occur in the absence of detectable malignant
process even after prolonged (more than 10 years) follow-up. In
such primary forms, a monoclonal bone marrow plasma cell
population is easily evidenced by cytoplasmic IF and Ig biosyn-
thesis experiments. It is worth noting that, in our experience, such
a monotypic population is obvious by IF in MIDD (with several %
monotypic plasma cells), whereas its detection requires a very
careful analysis in primary amyloidosis, in which clonal plasma
cells usually account for less than 1% of bone marrow nucleated
cells [29]. This suggests that the plasma cell mass required for the
clinical expression of the disease is larger in LCDD than in
amyloidosis.
It is worth noting that in 15% to 30% of patients with MIDD,
there is no detectable monoclonal Ig in the patients' serum and
urine. Some patients hence are affected with so-called nonsecre-
tory myeloma or macroglobulinemia, as long known in AL-
amyloidosis. Nonsecretory myeloma is unappropriately defined by
the absence of detectable serum and urine monoclonal 1g. True
nonsecretion is very rare [30]. In most cases, there is a secretion of
abnormal Ig molecules which are either rapidly degraded post-
synthetically or deposited in tissues [reviewed in 31].
Immunoglobulin abnormalities
Soon after the description of LCDD, it became apparent that L
chains may be structurally abnormal in this condition [13, 28], and
this was confirmed by further studies for both L and H chains.
Light and light and heavy chain deposition diseases
Monotypic Ig chain determinants are easily detectable by
immunohistochemical study in MIDD. In our experience (Table
2), the L chain type is often but not exclusively x, with a K/A ratio
of 4/1. It is worth noting that, in several cases with L chain but no
H chain deposits, the bone marrow plasma cells contained both H
and L chains. In such cases, biosynthesis experiments showed the
production of normal-sized H chains together with L chains and
the secretion of both assembled Ig molecules and free L chains.
The assembled molecules were detectable in the serum as entire
monoclonal 1g. As for the L chains, a urinary Bence Jones (BJ)
protein was found in urine when the L chain was apparently
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structurally normal and not when it was grossly abnormal. In the
latter cases, the abnormal L chains could be isolated from the
serum entire monoclonal Ig when present. In three cases, the
deposits contained both H and L chain determinants. As in two
similar cases studied by Buxbaum et a! [16], Ig biosynthesis study
performed in two of them showed truncated (short by about a
domain) H chains. These short H chains could not be further
studied. In a HCDD patient (see below), normal-sized L chains
and short H chains were non-covalently associated in a serum
monoclonal IgG in the absence of detectable free H chains and
only the H chains were deposited. Hence for both H and L chain
there is a positive correlation between structural abnormalities,
tissue deposition and the absence of the corresponding chains in
detectable amounts in serum and urine.
In our initial study of Ig biosynthesis by bone marrow plasma
cells in eight consecutive patients [13, 14, 28, 32], L chains were
normal-sized and secreted as monomers and dimers (as in com-
mon myeloma) in two cases. The L chains were grossly abnormal
in the six other patients. These abnormal L chains were either
short (2 cases) or apparently enlarged, with a relative molecular
mass (Mr) by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) of about 30 kDa (4 cases). The finding of
abnormally large L chains is significant for K chains whereas
certain A chains show an aberrant mobility by SDS-PAGE, leading
to erroneously apparently large Mr. These short or large L chains
showed a striking ability to polymerize by covalent bridges when
they were secreted in vitro by the monoclonal plasma cells. When
monomeric L chains were purified under dissociating conditions
from serum monoclonal IgG and set in non-dissociating medium,
they readily formed high molecular weight aggregates. In all six
patients, the Mr of the short or large L chains on SDS-PAGE gels
was higher in cell secretion than in the cytoplasm, which is highly
suggestive of glycosylation. This was confirmed in two cases by
biosynthesis experiments performed in the presence of the inhib-
itor of N-glycosylation tunicamycine and by the study of carbohy-
drates of two purified K chains. These L chains contained 11% and
15% carbohydrates, respectively, with a composition compatible
with N-glycosylation. In a further case, the apparently large K L
chain became normal-sized after treatment with N-glycosidase F
(unpublished results).
Recent data collected in a patient (BLU) affected with nonse-
cretory K myeloma provided the first complete sequence of a
LCDD L chain [33]. The large 30 kDa K chain found in the kidney
was presumably identical to that secreted by the malignant plasma
cells since they shared the same Mr and 13 N-terminal amino acid
sequence, and both were glycosylated. It resulted from the
translation of normal-sized K mRNA. K chain BLU proved by
biosynthesis study with '4C glucose incorporation and by N-
glycosidase F treatment to be N-glycosylated in the bone marrow
plasma cells. It was sequenced at the level of bone marrow cell
RNA. As in every LCDD L chain sequenced, the constant (C)
region was entirely normal. The variable (V) region belonged to
the VKIV subgroup. This made easy the comparison with germ-
line sequence since there is a single germline VKIV gene: the BLU
K chain bore eight mutations which could modify the conforma-
tion of the V domain. Substitutions were observed in the comple-
mentarity determining regions (CDR) 1 and 3, including replace-
ment of proline 95 (considered as being mainly responsible for the
conformation of the third hypervariable region) [34] and were
such that these regions did not fit with any of the canonical
structures defined for K hypervariable regions [35]. Substitutions
in the framework (FR)3 region included the replacement of Asp
by Asn at position 70 which determined a potential N-glycosyla-
tion site. It is worth noting that the same N-glycosylation site at
position 70 was found in an amyloidogenic K chain [36]. At
variance with the findings in the other patients, K chain BLU was
secreted as covalent monomers and dimers (no study could be
performed under non-dissociating conditions). Its sequence re-
vealed no extra cysteine residue that could be used in disulfide
bonds. Thus, glycosylation might play a direct role in tissue
precipitation.
The composition of the mesangial matrix increase in LCDD has
been examined only in a limited number of cases using antibodies
to basement membrane laminin and fibronectin [37]. The glomer-
uli contain an excess of extracellular matrix molecules (ECM)
comparable to those found in many instances of progressive
glomerular disease such as diabetes and membranoproliferative
glomerulonephritis. Whether the increase in the ECM is due to an
increase in biosynthesis and/or a decrease in the degradation and
whether the increase in the number of cells in the mesangial
spaces is due to an accelerated turnover rate, a decrease in
apoptosis, or to a combination of both is not yet firmly established.
The combination of an increased number of mesangial cells and of
an excess of extracellular matrix and results of a recent in vitro
study [38] suggest that deposited Ig chains may stimulate the
mesangial cells through growth factors released either from
blood-borne cells or produced by the local resident cells in an
autocrine fashion, similarly to advanced glycosylation end prod-
ucts (AGEs) [39, 40]. These adducts are believed to play a key role
in the development of diabetic glomerulosclerosis. They down-
regulate the production of nitrite oxide and block its anti-
proliferative effect [41, 42]. In vitro they can stimulate the
production of laminin B, basement membrane type IV collagen
and proteoglycans by cultured mesangial cells. Furthermore,
recent data [43] indicate that the injection of AGEs during three
weeks to naive mice results in an up-regulation of the glomerular
mRNA coding for al type IV collagen and laminin. The wide cell
and tissue distribution of the receptors for AGEs is reminiscent of
that of tissue lesions in LCDD [44]. Of course, AGEs are different
from N-glycosylated L chains [45, 46], but, although this has not
been investigated so far, the involvement of AGEs in MIDD
might be envisaged. In that respect, AGEs in large amounts have
been recently identified in the amyloid deposits of hemodialyzed
patient with 132 microglobulin-associated amyloid [47]. It is worth
pointing out that the deposits in LCDD are consistently PAS-
positive irrespective of L chain glycosylation.
As mentioned above, our early study showed normal-sized L
chains without evidence of glycosylation in 2 patients, whose urine
contained a BJ protein. We recently sequenced the K chains at the
level of bone marrow plasma cell mRNA in two further similar
cases. The K chain FRA [48] belonged to the VKIV subgroup and
was encoded by a normal-sized mRNA. The size of the L chain by
SDS-PAGE was slightly larger than that calculated from the
sequence. As the L chain was not glycosylated, this might suggest
a peculiar structure. The V region bore 17 amino acid substitu-
tions. Substitutions occurred at only three of the corresponding
positions in protein BLU and only one resulted in the same
residues in both K chains. Although five substitutions involved the
CDR1, one the CDR2 and three the CDR3, the hypervariable
regions fitted canonical structures. The K chain ISE [49] was of the
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Table 3. VK subgroup of MIDD K chains
VKI V,dI VKIII VidV
Number of cases 2 1 2 2
[reference] [49, 51] unpublished [50 and
unpublished]
[33, 48]
Overall distribution 56% 10% 20% 7%
among BJ proteins
[20]
Mr (kDa) 25 28 25 23 29 30 27
N-glycosylation no ? ? no yes yes no
BJ protein yes ? yes yes no no yes
VKI subgroup and again had an overall normal sequence. It
probably related to the HK1O2 gene and its V region bore a
number of substitutions also. Replacement of polar residues
that are likely exposed to the solvent resulted in the clustering of
seven hydrophobic amino acids in CDR1. Preliminary results of
molecular modeling suggest that this clustering indeed creates a
hydrophobic zone which might promote interactions favoring L
chain aggregation and tissue precipitation. In another patient
(Sci) whose normal-sized urinary K BJ protein was recently
studied, the K chain sequence was also special by the replacement
by a hydrophobic residue (lie) of residues located in regions
probably exposed to the solvant (Asn53 and Ser77) [50]. A
possible role of hydrophobicity is also suggested by the finding
of a unique Ile-Ile-Leu N-terminus in another K chain from a
LCDD patient (REV) which is presently under study in our
laboratory.
From our study, that of Buxbaum et al [16] and two cases from
the literature [50, 51], data on L chain size and ascertained or
probable glycosylation in 22 patients show that the L chains were
unglycosylated and normal-sized in 13 cases and glycosylated in 9
patients (short in 2 and clearly enlarged by SDS-PAGE as a likely
result of glycosylation and possibly aberrant conformation of the
V region in 7 cases). At variance with our results, Buxbaum et al
[16] found no evidence of glycosylation and size abnormality of
the L chains in seven cases. They noted the presence of L chain
fragments together with entire L chains in four of them, a
situation we have not encountered in MIDD. The reasons for
these discrepancies are unknown. They might reflect different
recruitments and the inclusion of patients with associated amy-
loidosis (see below) in the New York series. Indeed, both in
Buxbaum's study [52] and in ours [29], the finding of L chain
fragments in association with normal-sized L chains in biosynthe-
sis experiments appeared to be a special feature of amyloidosis.
The V region variability subgroup is known in only seven MIDD
cases so far (Table 3). In comparison with the known distribution
of VK subgroups among BJ proteins, there might be an overrep-
resentation of the VKIV subgroup, but the series is yet far too
short to draw any conclusion (note added in proof).
Heazy chain deposition disease
In a recently reported patient (ART) affected with systemic
amyloidosis, the amyloid component was a short chain, which
led to the denomination of AH-amyloidosis [7]. This truncated H
chain belonged to the yl subclass and contained a normal V
domain (a VH111 sequence contiguous with residues consistent
with D and J regions) directly linked to the third constant domain
(CH3). We just completed the study of two patients who pre-
sented with the nephrotic syndrome and hypertension [9]. Study
of kidney biopsies (Figs. 1 to 3) yielded results that were typical of
LCDD by light and electronmicroscopy (nodular glomeruloscie-
rosis with non-organized granular electron-dense deposits in the
nodules and along the basement membranes). However, by IF the
deposits strongly stained for y chains, whereas they were unreac-
tive with potent polyclonal and monoclonal anti-L chain conju-
gates. The first patient (THR) had myeloma with bone marrow
plasma cells staining for y and A chains by IF. Her serum and
urine contained both a normal-sized and a short (94 kDa by gel
filtration) IgG1A. The latter was made up of two short (24 kDa) y
chains non-covalently linked to a normal-sized A chain dimer.
Study of the short IgG by Western blotting with a panel of
monoclonal antibodies (mAb) to the various y chain domains
showed the absence of the epitopes recognized by the anti-CH1
and anti-CH2 antibodies. The same niAb reactivity pattern was
observed for the kidney-deposited y chains by IF. The sequence of
protein THR determined at the level of bone marrow plasma cells
by cDNA PCR showed a V region directly joined to a normal CH3
domain. This is strikingly similar to the AH-amyloidosis protein
ART, with a V region of the same \THIII subgroup and a CH3
domain of a y chain of the yl subclass which only showed allotypic
differences. Protein THR V region showed very unusual features
with eight residues that had not been reported at the correspond-
ing positions in known VHIII sequences but ART for one of
them.
The structure of THR and ART proteins is different from that
of heavy chain disease (HCD) proteins. HCD are monoclonal
lymphoid disorders characterized by the presence in the patient's
serum of truncated H chains lacking associated L chains, In every
case studied so far but one case with an isolated deletion of CH1
[53], part or all of the V domain of the H chain was deleted.
Except for a few i HCD cases featured by an isolated deletion
of the whole V domain [54], the CH1 domain is consistently
absent from HCD proteins, the normal sequence resuming most
commonly at the beginning of the hinge region or of the CH2
domain. Hence the most common abnormality of HCD proteins
is the presence of one or two often internal deletion(s) affect-
ing the V and CH1 domain [reviewed in 31, 55]. HCDs are known
for the three main Ig classes and they may be associated with
various forms of lymphoplasmacytic proliferations, very rarely
myeloma, or found in the absence of overt malignancy. There is
usually no kidney disease in HCD and the possibility of tissue
deposition of HCD proteins has not been definitely documented
so far. However, in a y HCD patient affected with amyloidosis of
unknown biochemical composition, enzymatic digestion of the
HCD protein resulted in the precipitation of Congo-red binding
material [56].
The second patient with HCDD [9] has a long history of
autoimmune disorders including hyperthyroidism then Hashimo-
to's thyroiditis, severe peripheral thrombopenia and various se-
rum autoantibodies. Her serum contained oligoclonal Ig (none
of the IgG4 isotype and with no detectable truncated H chain)
which likely related to long-term immunosuppressive therapy.
Deposits were found in the kidney, thyroid gland (Fig. 4),
arteriolar walls and in the asymptomatic liver Disse's spaces. By
IF, they stained for a H chain of the y4 subclass lacking epitopes
in the CH1 domain. Careful search for immunoproliferative
disorder was negative, as non-rarely in y HCD, a disease featured
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Table 4. Comparison of MIDD and immunoglobulinic amyloidosis'
MTDD Amyloidosis
Presentation Multivisceral or predominant involvement of an organ (kidney)
Monoclonal immunoproliferative disorders, mostly myeloma. Monoclonal bone marrow plasma cell populations
without Overt malignancy. Possibility of "nonsecretory" forms.
Underlying disease
Deposits by EM (granular) non-organized fibrillar (j3 pleated sheets)
Spectrum LCDD: L chains, most K, either apparently AL-amyloidosis: fragments of or normal-sized
enlarged, normal-sized or short. Frequent or apparently enlarged L chains most A.
glycosylation and polymeration. Abnormal susceptibility to proteolysis.
LHCDD: associated H chains (short by Cases with associated short H chains by
biosynthesis experiments) biosynthesis experiments
HCDD: short H chains only AH-amyloidosis: short H chains
L chain isotypy VKIV predominance VAVI CA3 predominance.
a Association is not exceptional
Fig. 4. HCDD (same patient as in Figs. 1 to 3). Thyroid gland biopsy.
Heavy staining by y chain antibodies of deposits around the basement
membranes of colloid vesicles (IF, original magnification X500). This
illustrates the wide tissue distribution of the deposition process which
includes organs that are clinically unaffected (for instance, liver involve-
ment is virtually constant by IF).
by the high frequency of autoimmune symptoms [55].An appeal-
ing but yet unsubstantiated hypothesis is that the patient might be
affected with (yet undescribed) "nonsecretory" y HCD, the
apparent nonsecretion being explained by tissue deposition. In
two further patients, both presenting with nodular glomerulo-
sclerosis, preliminary results showed serum IgGA with short
(40 to 45 kDa) yl chains [57]. These y chains as well as the kidney
y chains lacked epitopes in the CH1 domain. It is hence striking
that in every HCDD case studied so far, as presumably in
LHCDD, the deposited H chains were short by one or two
domains.
Cone iusion
Although LCDD was described only 15 years ago, the data
permit a description of the spectrum of MIDD and some insight
into disease pathogenesis. First reported for L chains, MIDD now
includes deposition of both monoclonal H and L chains and of
isolated H chains. This parallels the situation in amyloidosis
(Table 4). AL-amyloidosis was first described and accounts for
most cases. However, the finding of short H chains produced
together with an excess of L chains in some amyloidosis patients
by Ig biosynthesis studies [29, 521 may suggest (the amyloid
deposits were not studied in these patients) that both H and L
chains may be involved in tissue deposition in certain cases of
AL-amyloidosis. Finally, the description of AH-amyloidosis
shortly preceded that of HCDD. Ig biosynthesis patterns and the
probable mechanisms of MIDD and amyloidosis are different in
most cases but possibly rather similar in certain patients, which led
to expect the possibility of association in the same patients [14], a
hypothesis which was rapidly confirmed [15, 16, 58—60]. However,
the identity of the L chain present in both types of deposits in such
patients has not been documented. As in amyloidosis, a number of
converging arguments demonstrate or strongly suggest the direct
pathogenetic role of monoclonal Ig abnormalities or peculiarities
in MIDD: the correlation between the presence of Ig chain
abnormalities and tissue deposition, their simultaneous occur-
rence in treated myeloma patients, the recurrence of the disease
in grafted kidneys [61], the identity of the L chain in the kidney
deposits and bone marrow plasma cells demonstrated in a LCDD
[33] and an AL-amyloidosis [62] cases, the results of the injection
of pathogenetic L chains in experimental animals [63] and the
recent structural data showing abnormalities in L and H chains
variable regions (and sometimes H chain deletion leading to a H
chain similar by size and organization (a V and a C domain) to a
L chain). The unusual features of variable regions probably play a
key role in tissue deposition. This is also the case in the myeloma-
associated Fanconi's syndrome (in which the K chains are able to
generate a protease-resistant V region fragment, which is the
main component of the crystals, and show striking properties of
binding to themselves and to certain other K chains) [64]. How-
ever, both in MIDD and in AL-amyloidosis, no consistent pattern
emerges from comparison of V region sequences and the precise
mechanism(s) of tissue deposition remains unknown. Experi-
ments involving molecular modeling, site-ditected mutagenesis
and construction of experimental models (transfection in murine
plasmacytomas, chimeric or transgenic mice) and in vitro study of
Preud'homme et al: MJDD 971
interactions between Ig chains and cells or extracellular matrix are
presently undertaken in our laboratories, with the liope to get
some more insight into this yet puzzling question.
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